RXMD IS A CAUSE FOR CELEBRATION THIS IS A MUCH CLEARER PICTURE Must show the entire PIE not just a piece of the PIE, and sticking to the facts helps a whole whole lot too.
THERE ARE ONLY GOOD MONTHS HERES SOME JUICY 2018 NUMBERS W/O NEW LOCATION 24% Scripts increase compared to March 31, 2017 $300,000+ Net Revenue increase compared to March 31, 2017 $870,000+ 340B sales increase compared to March 31, 2017
Then let’s observe increase in revenue last year. Then check out increase in revenue from the last 2 years. Overall G - FY 2013 = $9.3 million R - FY 2014 = $11.3 million O - FY 2015 = $13.7 million W - FY 2016 = $18.3 million T - FY 2017 = $20.1 million H - FY 2018 = $5.15+ million (1 quarter)
LET'S TALK ABOUT INCOME Shall We . . . FY 2017 = $49,251 Net Income FY 2016 = $209,319 Net Income Yes it did go down by $150,000, but quite explainable with information detailed below and still extraordinary when you consider the improvement from 2015 and 2014, FY 2015 = $(1,219,000) Net Loss FY 2014 = $(1,009,000) Net Loss
Now let’s analyze where some of expenses effecting additional net income has been applied to development, growth, and expansion initiatives. Growing, Growing, Growing. Everything says they are using money to GROW.
Also management has restructured Key Pharmacist agreement, which could result in the following increases to Net Income for 2018 and beyond. Set to save $521K in costs for 2018 alone.
And The Available Cash Is Half As Much !!! End Of 2016 = $816K ... End Of 2017 = $419K
Only a decrease when you show half the information, but when recorded with Accounts Receivable FY 2016 A/R = $867,769 FY 2017 A/R = $1,270,114 Cash and A/R = Cash Equivalents December 31, 2016 = $1,683,000 December 31, 2017 = $1,689,000 Still in great condition, no decrease here. Actually an increase of $6K and liabilities also decreased by $95K, for a net positive change of $101K.
EVERYTHING IS MOVING FORWARDS AND LOOKING GREAT !!!
SHORT TERM PRICE TARGET $.35
"To Give Anything Less Than Your Best, Is To Sacrifice the Gift." - Steve Prefontaine